Genentech, Chiron Settle Herceptin Patent Dispute

Law360, New York (August 3, 2005, 12:00 AM EDT) -- Biotech companies Genentech, Inc. and Chiron have quietly settled the remaining patent disputes in a $300 million lawsuit over Genentech's metastatic breast cancer drug, Herceptin (Trastuzumab).

The deal was disclosed Tuesday by Genentech in a regulatory filing to the U.S. Securities and Exchange Commission.

Genentech and Chiron settled their dispute in June, ending both interference proceedings at the U.S. Patent & Trademark Office and a lawsuit that had been appealed to the U.S. Court of Appeals for the Federal Circuit.

“Under the settlement agreement, Chiron has...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.